Baird raises target for Intuitive Surgical stock from USD 513 to USD 550
Published on 10/26/2026 at 11:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst targets and operating growth
- Baird raised its Intuitive Surgical target from USD 513 to USD 550 on October 21, 2026.
- Third-quarter 2026 revenue reached USD 3.05 billion, up 22 percent year over year.
- Intuitive Surgical stock trades at EUR 405.05 at 11:50 a.m. CEST at Lang & Schwarz on October 26, 2026, 0.39 percent below the Xetra close of October 23, 2026.
Intuitive Surgical (ISIN US46120E6023) was trading at EUR 405.05 at Lang & Schwarz on October 26, 2026, at 11:50 a.m. CEST, 0.39 percent below the Xetra close of October 23, 2026 at EUR 406.65. The latest catalyst is a post-results reset in analyst targets: according to Benzinga on October 21, 2026, Baird raised its target from USD 513 to USD 550.
Results reset the valuation debate
Intuitive announced its third-quarter 2026 results on October 20, 2026. The company reported revenue of USD 3.05 billion for the quarter ended September 30, 2026, an increase of 22 percent from USD 2.51 billion a year earlier, according to Intuitive Surgical.
The headline growth came with a sharp accounting contrast. GAAP net income attributable to Intuitive Surgical fell to USD 522.8 million from USD 704.4 million because the quarter included a USD 454.9 million litigation charge. Non-GAAP net income reached USD 1.05 billion, or USD 3.00 per diluted share, versus USD 867.2 million and USD 2.40 a year earlier, according to the company release.
What does the procedure outlook mean?
Management expects worldwide da Vinci procedure growth of 14 percent to 15 percent in full-year 2026 and a non-GAAP gross profit margin of 68.7 percent to 69.3 percent. That outlook puts operating execution beside the legal charge as the key valuation variable.
Three milestones shaped the year
On July 27, 2026, Intuitive listed a collaboration with Deion Sanders; on September 8, 2026, it highlighted a meta-analysis covering 13 benign conditions; and on October 20, 2026, it reported USD 3.05 billion in third-quarter revenue, according to the company investor overview and release.
Stock and target context
Baird's USD 550 target was one of several revisions after the results, while Mizuho cut its target from USD 415 to USD 400 and RBC reduced its target from USD 575 to USD 550, according to Benzinga. The mixed target actions show that procedure growth is being weighed against valuation and litigation effects.
Trading reference for investors
Intuitive Surgical stock was trading at EUR 405.05 at Lang & Schwarz on October 26, 2026, at 11:50 a.m. CEST, 0.39 percent below the Xetra close of October 23, 2026 at EUR 406.65. The company is listed on Nasdaq under ISRG, according to its investor-relations page.
The further course of trading is shown by the continuously updated real-time quote of Intuitive Surgical stock.
Intuitive Surgical stock facts
- Company: Intuitive Surgical, Inc.
- ISIN: US46120E6023
- Ticker: ISRG
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 26, 2026, 11:50 a.m. CEST): EUR 405.05
- Change versus Xetra close: minus 0.39 percent
- Xetra close (October 23, 2026): EUR 406.65
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: S&P 500
Market context: Market report S&P 500.
